Trial to Evaluate Safety and Immunogenicity of INO-5150 Alone or With INO-9012 in Men With Prostate Cancer

Prostate Cancer Clinical Trial

Official title:

Phase I, Open-label Trial to Evaluate the Safety and Immunogenicity of INO-5150 Alone or in Combination With INO-9012 in Men With Biochemically Relapsed (PSA) Prostate Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02514213
• Other study ID #: PCa-001
• Status: Completed
• Phase: Phase 1
• First received: July 29, 2015
• Last updated: December 21, 2017
• Start date: July 2015
• Est. completion date: December 12, 2017

Study information

• Verified date: December 2017
• Source: Inovio Pharmaceuticals
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a phase I, open-label trial to evaluate the safety and immunogenicity of INO 5150 alone or in combination with INO-9012 when delivered intramuscularly (IM) followed by electroporation (EP) in men with biochemically relapsed prostate cancer.

Description:

Phase I, open label study of INO-5150 (DNA plasmids encoding prostate specific antigen (PSA) and prostate specific membrane antigen (PSMA)) alone or co-administered with INO-9012 (IL-12 plasmid) delivered intramuscularly followed by EP using the CELLECTRA®-5P device in adult males with biochemically relapsed prostate cancer following definitive local therapy (e.g. prostatectomy, external beam radiation, or brachytherapy). Four injections will be administered to approximately 60 eligible subjects who consent to participate in the study. Subjects will be monitored for safety and immunogenicity through Week 72.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 62
• Est. completion date: December 12, 2017
• Est. primary completion date: December 12, 2017
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years to 90 Years

Eligibility

Inclusion Criteria:

1. Men aged 18 to 90 years with a histologic diagnosis of prostate cancer;

2. c. Biochemical recurrence following local therapy, either surgery or radiation. Rising PSA defined as:

• After definitive surgery, e.g.

• After radical prostatectomy, two PSA measurements of = 1.0 ng/mL at least one week apart;

• After cryosurgery, two PSA measurements of = 2.0 ng/mL at least one week apart;

• Other definitive surgical procedures may be permissible upon the approval of the medical monitor OR

• After radiation therapy (e.g., external beam radiation, brachytherapy, or salvage/adjuvant radiation therapy after surgery), two post radiation PSA measurements level of nadir plus 2.0 ng/mL at least one week apart.;

3. Serum testosterone level:

i) Subjects with no history of androgen deprivation therapy:

• A single measurement greater than 150 ng/dL or 5.2 nmol/L within 3 months of enrollment

ii) Subjects with a history of androgen deprivation therapy (either in adjuvant or biochemical relapse setting):

• The two most recent measurements of serum testosterone prior to enrollment must fulfill the following criteria:

• Both measurements are greater than 150 ng/dL or 5.2 nmol/L;

• The two measurements are spaced at least 14 days apart;

• Both must be measured within 3 months of enrollment;

4. Normal electro cardio gram (ECG) or ECG with no clinically significant findings;

5. Adequate bone marrow, hepatic, and renal function tests within 30 days prior to enrollment:

• CBC (except platelets and hemoglobin), serum chemistry, liver panel, and CPK values = Grade 1 abnormality as defined in CTCAE v 4.03 dated June 14, 2010

• Platelets = 75,000 /mL;

• Hemoglobin = 9.0 g/dL;

6. No desire or plans to father new children during the study and/or have a prior vasectomy

Exclusion Criteria:

1. PSA doubling time (PSA-DT) of = 3 months, using 2 PSA values at least 4 weeks apart, calculated according to the Memorial Sloan-Kettering Cancer Center nomogram (https://www.mskcc.org/nomograms/prostate/psa-doubling-time);

2. Clinical or radiologic evidence of distant metastatic disease other than small volume (<1.5 cm) nodes, this should be tested within 12 months from enrollment;

3. Receipt of investigational therapy in a clinical trial setting within 30 days of enrollment;

4. Any pre-excitation syndromes, e.g., Wolff-Parkinson-White syndrome;

5. Prior major surgery or radiation therapy within 4 weeks of enrollment;

6. Any prior chemotherapy, except short-course neo-adjuvant or adjuvant chemotherapy that had been stopped for at least 6 weeks prior to Study enrollment;

7. Active AIDS / HIV infection, clinically uncontrolled immune deficiency disorders;

8. Clinically uncontrolled autoimmune disorders, transplant recipients who depend on immunosuppressive therapy, other immunosuppressive conditions including any concurrent condition requiring immunosuppressive/immunomodulating agents;

9. Recipient of any blood product and immunotherapy (such as anti-PD1, anti-PDL-1 and anti-CTLA4) within 3 months of enrollment;

Related Conditions & MeSH terms

• Prostate Cancer
• Prostatic Neoplasms

Intervention

Biological:
• 2mg INO-5150 and electroporation device CELLECTRA®-5P
2mg INO-5150 delivered IM followed by electroporation using CELLECTRA®-5P
• 8.5mg INO-5150 and electroporation device CELLECTRA®-5P
8.5 mg INO-5150 delivered IM followed by electroporation using CELLECTRA®-5P
• 2mg INO-5150 plus 1mg INO-9012 and electroporation device CELLECTRA®-5P
2mg INO-5150 plus 1 mg INO9012 delivered IM followed by electroporation using CELLECTRA®-5P
• 8.5mg INO-5150 plus 1mg INO-9012 and electroporation device CELLECTRA®-5P
8.5mg INO-5150 plus 1 mg INO9012 delivered IM followed by electroporation using CELLECTRA®-5P

Device:
• Electroporation using CELLECTRA®-5P
Electroporation device CELLECTRA®-5P

Locations

Country	Name	City	State
United States	Chesapeake Urology Research Associates	Baltimore	Maryland
United States	University of North Carolina Lineberger Cancer Center	Chapel Hill	North Carolina
United States	Cleveland Clinic	Cleveland	Ohio
United States	Karmanos Cancer Institute	Detroit	Michigan
United States	Carolina Urologic Research Center	Myrtle Beach	South Carolina
United States	Weill Cornell Medical College	New York	New York
United States	GU Research Network, LLC/ Urology Cancer Center	Omaha	Nebraska
United States	Sidney Kimmel Cancer Center - Thomas Jefferson University	Philadelphia	Pennsylvania
United States	UPMC	Pittsburgh	Pennsylvania
United States	Seattle Cancer Care Alliance	Seattle	Washington

Sponsors (1)

Lead Sponsor	Collaborator
Inovio Pharmaceuticals

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety and tolerability of INO-5150 alone or with INO-9012 delivered via IM EP ( Incidence of adverse events, Injection site reactions, Changes in safety laboratory parameters)	Incidence of adverse events (all, severe, [NCI CTCAE v4.03] and serious) classified by system organ class (SOC), preferred term, severity, and relationship to study medication and schedule; Injection site reactions; Changes in safety laboratory parameters .	72 weeks
Primary	Antigen specific immune response of INO-5150 alone or with INO-9012 delivered via IM EP	Antigen specific cellular immune responses	72 weeks
Secondary	PSA response rate by PSA testing	PSA response	72 weeks